SGLT2 Inhibitors in HF — Barriers in Jordan (Mixed-Methods Study, 2026)
SGLT2 Inhibitors in HF — Barriers in Jordan (Mixed-Methods Study, 2026)
Source :
• Frontiers in Pharmacology
• Published: April 7, 2026
• DOI: http://doi.org/10.3389/fphar.2026.1803731
Study Design
• Mixed-methods study = combines:
* Quantitative data (survey)
* Qualitative insights (interviews)
Data Components
• Survey:
* 312 physicians in Jordan
* 214 treating physicians
* 98 insurance physicians
• Interviews:
* 22 physicians
* In-depth qualitative analysis
What the data actually represent :
• Survey analysis only
👉 No patient-level registry data were used in this study. The authors only cited national registry findings as background to support the low utilization rates.
Key Findings
• Low use of SGLT2 inhibitors in HF despite good physician knowledge
• Insurance approval (HF without diabetes): < one-third
• Strongest predictor of rejection:
* Misclassification as “diabetes-only drugs” (61.2%)
• Higher approval when prescribed by cardiologists
• Main issue:
🎯 Take-home
👉 This is a survey-based system analysis
👉 Highlights need for national registry-driven data
